Development of a Radiation Oncology Fee Schedule Model for Industry-Sponsored Clinical Trials
Janis V. de la Iglesia, Eduardo G. Moros(Moffitt Cancer Center), K. Yamoah, Kujtim Latifi(Moffitt Cancer Center), J.J. Caudell(Moffitt Cancer Center)
International Journal of Radiation Oncology*Biology*Physics
September 27, 2024
Cited by 0
Related Papers
Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck: ASCO Guideline
|Journal of Clinical Oncology|2020|221
Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer
|International Journal of Radiation Oncology*Biology*Physics|2023|18
Magnetic Resonance Guided Radiotherapy for Rectal Cancer: Expanding Opportunities for Non-Operative Management
|Cancer Control|2020|12
A phase II, randomized study of nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and stereotactic body radiation therapy (SBRT) for metastatic Merkel cell carcinoma (MCC, NCT03071406): A preliminary report
|Annals of Oncology|2019|5
NBTXR3 Radiation Enhancing Hafnium Oxide Nanoparticles Activated By Radiotherapy In Combination With Anti-PD-1 Therapy: A Phase I Study
|International Journal of Radiation Oncology*Biology*Physics|2020|4